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and outcome of pyelonephritis from an RCT comparing
TMP-SXT with ciprofloxacin (Talan, JAMA, 283:1583–
1590,2000). METHODS: In the trial cost analysis was
limited to a comparison between the two treatment
groups, which did not permit analysis of effect modifiers,
such as TMP-SXT resistance. A probabilistic model was
developed and distributions were assigned to expected
costs and probabilities of cure, failure (persistent or re-
current infection) and superinfection (reinfection with a
new organism) from the trial data. These distributions,
which characterise the second order uncertainty sur-
rounding these outcomes following the trial, were propa-
gated through the model using Monte Carlo simulation
in order to generate cost-effectiveness acceptability curves.
RESULTS: There were 255 patients in the per protocol
analysis. The mean cost for patients with treatment fail-
ure ($476, n  34) was significantly higher than the cost
for patients who were either cured ($307, n  174) or
had superinfection ($325, n  11). However, treatment
with ciprofloxacin reduced both the probability and cost
of treatment failure (the mean difference in treatment
cost between success and failure was only $4 in the cipro-
floxacin arm compared with $267 in the TMP-SXT arm).
The probability that ciprofloxacin was dominant (greater
efficacy at lower cost) was 95% at 18% TMP-SXT re-
sistance and remained 95% down to a resistance rate of
10%. These results were sensitive to a small number of
hospitalisations (1 ciprofloxacin, 5 TMP-SXT). Taking
outpatient costs alone, the threshold value of treatment
failure at which ciprofloxacin was 90% likely to be cost-
effective ranged from $700 for 18% resistance to $350
for 30% resistance. CONCLUSIONS: The stochastic model
produces results that are importantly different from a
simple analysis based on point estimates of probability
and cost, particularly if the latter assumes that the cost of
treatment failure is the same for both treatments.
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BACKGROUND: There is increasing concern about the
potential effects of the lipodystrophy syndrome on the health
and quality of life of HIV-infected patients. OBJECTIVE:
Understand patients’ perception of the significance of the
lipodystrophy syndrome’s quality-of-life effects. DESIGN:
Cross-sectional study of volunteer HIV-infected patients.
SETTING: An urban, university-affiliated HIV clinic in
San Diego, California. Patients: 75 well-educated, predom-
inantly male, HIV-infected patients. MEASUREMENTS:
Patients’ beliefs about the importance of appearance upon
quality of life and preferences for hypothetical states per-
formed using the standard gamble and time trade-off
methods. RESULTS: Almost all patients (95%) indicated
that appearance was important to their quality of life,
and 89% agreed that they would be “really bothered” if
their HIV diagnosis were revealed by their appearance.
Patients were willing, on average, to give up 2 years (s.d.
2.8), out of a 10-year life-expectancy, to live in good
health rather than live with the syndrome, over and
above what they would give up to be free of symptoms
from HIV infection. Patients would take an additional
13% (s.d. 20%) risk of death to be cured of HIV infec-
tion when complicated by the syndrome (median increase
in risk, 9%), above the risk they would accept to be cured
of uncomplicated HIV infection. The amount that the pa-
tients would trade off was associated with beliefs about
the importance of their appearance to quality of life (p 
0.0045) and worry that their appearance would expose
their diagnosis by (p  0.032). CONCLUSIONS: The
physical effects of the lipodystrophy syndrome are impor-
tant enough to cause many patients to consider accepting
considerable risks of death or trading off substantial life-
expectancy to avoid the syndrome. Physicians may need
to tailor HIV care to this aspect of patients’ preferences.
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OBJECTIVE: Intranasal influenza vaccine has proven
clinical efficacy and may be better tolerated by young
children and their families than an injectable vaccine.
This study determined the potential cost-effectiveness
(CE) of intranasal influenza vaccine among healthy chil-
dren. METHODS: The CE analysis included clinical and
medical utilization data collected in 1996–8 during a pro-
spective 2-year efficacy trial of intranasal influenza vac-
cine. These data were supplemented with data from the
literature where necessary. The analysis included both di-
rect and indirect costs. The trial enrolled 1,602 healthy
children 15–71 months of age in year 1, 1,358 of whom
were enrolled in year 2. Children received 1 or 2 doses of
either intranasal influenza vaccine or placebo. The main
outcome measure was cost per febrile influenza-like ill-
ness (ILI) day avoided. The base case assumed that the
vaccine was given twice in the first year and once each
year thereafter at a total cost of $20 for the vaccine and
its administration (i.e. per dose). RESULTS: Vaccinated
children had an average of 1.2 fewer ILI fever days over 2
years than unvaccinated children. In an individual-based
vaccine delivery scenario, CE was approximately $30/
febrile ILI day avoided with the vaccine, and ranged from
$10–$59/febrile ILI day avoided at a cost per dose of
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$10–$35, respectively. In a group-based delivery sce-
nario, vaccination was cost-saving compared to no vac-
cine and remained so if the vaccine cost was $28/dose
(the break-even price). In the individual-based scenario,
vaccination was cost-saving if the cost was $5/dose. In
this scenario, nearly half of lost productivity in the vac-
cine group was attributable to visits to administer the
vaccine, which overshadowed the relatively modest sav-
ings in ILI-associated costs averted. CONCLUSIONS:
Routine use of intranasal influenza vaccine among healthy
children may be cost-effective and may be maximized by
using group-based vaccination approaches.
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INTRODUCTION: The American College of Chest Phy-
sicians/Society of Critical Care Medicine Consensus Con-
ference defined severe sepsis as a systemic inflammatory
syndrome in response to infection associated with acute
organ dysfunction. Often, septicemia codes have been
used in administrative datasets as a proxy for severe sep-
sis. However, these entities are not necessarily the same
and one study found large differences in mortality be-
tween septicemia patients with and without severe sepsis
(54% vs. 15%). We explored the accuracy of septicemia
codes as identifiers of severe sepsis. METHODS: We se-
lected all patients with septicemia or severe sepsis (bacte-
rial or fungal infection plus acute organ failure) in the
1996 Florida hospital discharge database (n  1,936,479)
and compared differences between the groups. Septicemia
was defined using the ICD-9-CM code 038.xxx. We de-
fined severe sepsis using a more sophisticated strategy pre-
viously validated against prospective clinical and physio-
logic criteria. RESULTS: We found 58,598 patients with
severe sepsis, 53.4% of whom were in the intensive care
unit (ICU). We found 57,875 patients with septicemia,
30.9% of whom were in the ICU. Patients with severe
sepsis had a higher mortality (24.1% vs. 18.0%, p 
0.001) and higher hospital costs ($20.4k vs. $14.4k, p 
0.001). For patients with an ICU stay, hospital mortality
was 14.4% among the 7,927 septicemia cases without se-
vere sepsis, 23.5% among the 21,655 cases of severe sep-
sis without septicemia and 42.1% among the 9,970 cases
of severe sepsis with septicemia. The mean hospital cost in
these three groups was $18,381, $24,396, and $33,470
respectively. Of all selected patients (n  99,126), 17.5%
met criteria for both septicemia and severe sepsis. The
sensitivity and positive predictive values of septicemia
codes as predictors of severe sepsis are 29.6% and 30.0%
respectively. CONCLUSIONS: Septicemia codes are not
accurate for identifying patients with severe sepsis.
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BACKGROUND: The Medi-Cal program in California
added second-generation antipsychotic medications to its
formulary in October 1997. OBJECTIVE: Investigate the
impact of the formulary expansion on patient outcomes
for olanzapine and risperidone patients before and after
the formulary expansion. STUDY POPULATION: The
study population consisted of 13,106 olanzapine and
15,718 risperidone ambulatory patients from the 100%
Medi-Cal dataset, who were classified into 3 groups.
New: no previous antipsychotic drug therapy history. Re-
starters: re-started antipsychotic drug therapy while not
on active therapy. Switcher: who switched to one of these
products while on active drug therapy. METHODS:
Models of one-year treatment costs were estimated using
both OLS regression and propensity score methods.
Models included over 85 covariates for patient demo-
graphics, prior use of services, prior antipsychotic drug
profile and diagnostic profile. Separate models were esti-
mated for the 3 patient populations. Outcomes include
total costs over one year broken down into component
costs and days of uninterrupted drug therapy achieved af-
ter re-starting therapy. RESULTS: The formulary expan-
sion immediately increased the number of new, switcher,
restarter patients starting therapy with risperidone and
olanzapine. Olanzapine patients were more likely to be
male, between the ages of 30 and 60, urban residents and
AFDC recipients. For restarters and switchers, Olanza-
pine patients also appear to be more compliant with their
prior antipsychotic drug regimen. Once these differences
were accounted for, Risperidone and olanzapine patients
exhibited similar treatment cost profiles in the post-
expansion period. CONCLUSIONS: More research is
needed to determine if the formulary expansion reduced
the cost of treating patients with schizophrenia. Further-
more, future comparison across drugs must take into ac-
count potential treatment selection bias and formulary
expansion effects on the decision to start drug therapy.
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OBJECTIVE: Antipsychotic therapies are often evaluated
on the basis of clinical endpoints (BPRS, PANSS) and
measures of direct cost. However, schizophrenia patients
